Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • Novartis, Lonza...

    Novartis, Lonza strengthen biosimilars push with MS, arthritis drug deals

    Medical Dialogues BureauWritten by Medical Dialogues Bureau Published On 2019-09-03T09:30:38+05:30  |  Updated On 17 Aug 2021 11:52 AM IST

    Novartis's Sandoz generics unit, among the biggest biosimilars makers, on Tuesday, agreed to license from Poland's Polpharma Biologics a version of Biogen's decade-old Tysabri for multiple sclerosis. This is the fifth proposed biosimilar licensed by Sandoz in nine months.


    ZURICH: Swiss drugmakers Novartis and Lonza separately deepened their push into so-called biosimilars, betting cheaper copies of name-brand drugs will make headway among cost-conscious insurers and governments.


    Novartis's Sandoz generics unit, among the biggest biosimilars makers, on Tuesday, agreed to license from Poland's Polpharma Biologics a version of Biogen's decade-old Tysabri for multiple sclerosis. This is the fifth proposed biosimilar licensed by Sandoz in nine months.


    Meanwhile, Lonza announced it had contracted drug substance production for South Korean drugmaker Celltrion's Remsima, a copy of Johnson & Johnson's Remicade against autoimmune diseases like rheumatoid arthritis.


    Biosimilar versions of patent-expired blockbusters such as Remicade and Tysabri have advanced in Europe, although U.S. adoption has lagged as drugmakers fiercely defend original versions. Novartis has lost its share of fights, including a recent court setback over Amgen's Enbrel.


    Rebates offered to U.S. insurers by drugmakers have also erected barriers, although with markets like MS and immunology each in the tens of billions of dollars the allure remains great. This year, Canada's British Columbia province began switching patients to biosimilars in a bid to save tens of millions of dollars.


    Lonza Chief Executive Marc Funk said his Basel-based company, which helps other drug firms outsource their production, would give Celltrion "the flexible capacity and agile teams it needs to respond to evolving market demand".


    With their deal, Novartis and Sandoz add to a growing stable of MS drugs, including older Gilenya and newly approved Mayzent, as well as a late-stage biological hopeful, of Atumumab, in its pipeline.


    "Biosimilars create competition and cost savings, which are proven to make room in healthcare systems to treat more patients," said Pierre Bourdage, Sandoz's interim biopharmaceuticals head, without giving financial details of the deal for the Polpharma molecule now in late-stage trials.


    Novartis could have decent luck with MS biosimilars, analysts said, given the high costs of the debilitating disease for health systems. "The acceptance for cheaper MS medicines will be great because around half of all patients cannot afford them," ZKB analyst Michael Nawrath wrote in a note.


    Copies of biological drugs are called biosimilars because, unlike small-molecule chemicals, they cannot be exactly replicated in the factory. Still, studies show they carry the same potential benefits for patients.


    Read Also: Delhi HC given Green Signal to Natco Pharma for generic of Novartis cancer drug Ceritinib

    arthritis drugautoimmune diseasesBiopharmaceuticalsbiosimilarEnbrelImmunologyJnJJohnson & JohnsonLonzaMarc FunkMichael NawrathMS drugmultiple sclerosisNovartispharmapharma companypharma newsPolpharmaRemicadeRemsimarheumatoid arthritisSandozTysabri
    Source : Reuters

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Medical Dialogues Bureau
    Medical Dialogues Bureau

      Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers.  Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in. Check out more about our bureau/team here

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok